Search

Cilj istraživanja: Cilj ovog istraživanja je bio utvrditi razlike u razdiobi indeksa fibroze jetre (FIB-4) u osoba sa šećernom bolesti tipa 2 i ispitati utjecaj drugih varijabli na FIB-4 kao što su duljina trajanja šećerne bolesti, preboljenje i težina COVID-19, HbA1c i laboratorijski parametri te utvrditi postojanje međuovisnosti navedenih varijabli. Materijali i metode: U istraživanje je uključeno ukupno 100 ispitanika. Svi ispitanici koji su sudjelovali u istraživanju liječe se od šećerne bolesti tipa 2 u Centru za dijabetes KBC-a Split. Ispitanici su ispunili anketni upitnik koji je sadržavao pitanja o općim podacima ispitanika i ispitanikove šećerne bolesti, informacije o preboljenju i težini SARS-CoV2 infekcije te informacije o cjepnom statusu. Zabilježeni su antropometrijski parametri (visina, težina i BMI) te su uzeti podaci iz laboratorijskih testova (HbA1c, ALT, AST, trombociti i lipidogram). Uz pomoć trombocita, jetrenih enzima (ALT i AST) i broja godina pacijenta, izračunat je FIB-4 indeks. Rezultati: Nije zabilježena statistički značajna razlika prilikom usporedbe FIB-4 indeksa s obzirom na preboljenje (P=0,539) i težinu kliničke slike COVID-19 (P=0,137). Također, nije se pokazala značajna razlika kod usporedbe pojedinih vrijednosti indeksa fibroze jetre s obzirom na preboljenje (P=0,539) i težinu kliničke slike (P=0,289) COVID-19. Prilikom usporedbe vrijednosti HbA1c i FIB-4 indeksa, pokazala se blaga, ali statistički neznačajna korelacija (P=0,126). Također, nije se pokazala značajna razlika kod usporedbe HbA1c između različitih kategorija FIB-4 (P=0,587). Nije se pokazala značajna razlika u distribuciji težine bolesti između cijepljenih i necijepljenih pacijenata (P=0,539). Kod usporedbe razina HbA1c s obzirom na težinu COVID-19 se nije pokazala značajna razlika. Kod usporedbe FIB-4 indeksa s obzirom na duljinu trajanja šećerne bolesti, pokazala se statistički neznačajna korelacija (P=0,109). Između koncentracije FIB-4 i vrijednosti TG-a, LDL-a, HDL-a i ukupnog kolesterola pokazala se negativna statistički neznačajna korelacija (P=0,253, P=0,833, P=0,269, P=0,957). Zaključci: Ovo istraživanje je pokazalo da se distribucija FIB-4 indeksa nije statistički značajno promijenila u ovisnosti o preboljenju COVID-19, težini kliničke slike COVID-19, vrijednostima HbA1c-a, duljini trajanja šećerne bolesti te o abnormalnim vrijednostima lipida u krvi. Također, nije pronađena statistički značajna razlika u distribuciji težine bolesti između cijepljenih i necijepljenih pacijenata. Nisu zabilježene ni značajno veće vrijednosti HbA1c u osoba s težom kliničkom slikom COVID-19. Postoje statistički signali za gotovo sve pretpostavljene ishode te je za očekivati da bi istraživanje s većim brojem bolesnika potvrdilo ove hipoteze., Objectives: The aim of this study was to determine the differences in the distribution of the liver fibrosis index (FIB-4) in people with type 2 diabetes and to examine the influence of other variables on FIB-4 such as the duration of diabetes, recovery and severity of COVID-19, HbA1c and laboratory parameters and determine the existence of interdependence of the mentioned variables. Subjects and methods: A total of 100 respondents were included in the research. All subjects who took part in the research are being treated for type 2 diabetes in the Diabetes Center of KBC Split. Respondents filled out a survey questionnaire that contained questions about the respondent's general information and the respondent's diabetes, information on recovery and severity of SARS-CoV2 infection, and information on vaccination status. Anthropometric parameters (height, weight and BMI) were recorded and data from laboratory tests (HbA1c, ALT, AST, platelets and lipidogram) were taken. With the help of platelets, liver enzymes (ALT and AST) and the age of the patient, the FIB-4 index was calculated. Results: No statistically significant difference was found when comparing the FIB-4 index with regard to recovery (P=0.539) and the severity of the clinical symptoms of COVID-19 (P=0.137). Also, no significant difference was shown when comparing individual liver fibrosis index values with regard to recovery (P=0.539) and the severity of the clinical symptoms (P=0.289) of the COVID-19. When comparing the values of HbA1c and FIB-4 index, a slight but statistically insignificant correlation was shown (P=0.126). Also, no significant difference was shown when comparing HbA1c between different FIB-4 categories (P=0.587). There was no significant difference in the distribution of disease severity between vaccinated and unvaccinated patients (P=0.539). When comparing HbA1c levels with regard to the severity of the COVID-19, no significant difference was shown. When comparing the FIB-4 index with regard to the duration of diabetes, a statistically insignificant correlation was shown (P=0.109). A statistically insignificant negative correlation was shown between the concentration of FIB- 4 and the values of TG, LDL, HDL and total cholesterol (P=0.253, P=0.833, P=0.269, P=0.957). Conclusion: This research showed that the distribution of the FIB-4 index did not change statistically significantly depending on the recovery from the COVID-19, the severity of the clinical picture of the COVID-19, the HbA1c values, the duration of diabetes and the abnormal blood lipid values. Also, no statistically significant difference was found in the distribution of disease severity between vaccinated and unvaccinated patients. No significantly higher HbA1c values were recorded in persons with a more severe clinical picture of COVID-19. There are statistical signals for almost all assumed outcomes, and it is to be expected that research with a larger number of patients would confirm these hypotheses